Key Takeaways
- Bernstein maintains “outperform” rating on AstraZeneca with £186 price target, suggesting approximately 37% potential gains from £135.54 closing level
- The firm forecasts non-oncology products will account for roughly 65% of AstraZeneca’s anticipated 6% annual revenue growth through 2026–2031, yet remains undervalued by markets
- The broker’s $89.06B revenue projection for 2030 exceeds AstraZeneca’s internal $80B target by 11% and surpasses Bloomberg’s $82B consensus by 8%
- Wainua revenue estimates for 2035 reach $4.80B at Bernstein — nearly triple Bloomberg’s $1.80B consensus figure
- Shares gained 3.1% on June 4, reaching $181.80; insider activity shows $2.2M in sales over three months without offsetting purchases
Shares of AstraZeneca (AZN) advanced 3.1% during trading on June 4, 2026, settling at $181.80. The pharmaceutical giant’s stock currently fluctuates within a 52-week band spanning $134.90 to $212.71.
Bernstein released research on Friday maintaining its “outperform” stance on AstraZeneca shares. The firm held steady with its £186 price objective, measured against Friday’s £135.54 close — translating to approximately 37% potential upside.
The central thesis is straightforward: AstraZeneca’s non-cancer therapeutic portfolio remains significantly undervalued by market participants.
According to Bernstein, this division is positioned to contribute approximately 65% of the pharmaceutical company’s forecasted 6% compound annual revenue expansion spanning 2026 through 2031. Despite this projection, the analysts note it continues to receive insufficient focus “in the investment debate.”
The brokerage’s revenue projection for 2030 reaches $89.06 billion. This figure exceeds AstraZeneca’s internal risk-adjusted target of $80 billion by 11% and tops Bloomberg’s consensus estimate of $82 billion by 8%. The firm attributes all anticipated revenue outperformance versus consensus projections from 2027 through 2035 to the non-oncology portfolio.
Wainua Represents Largest Valuation Gap
The most significant variance centers on Wainua, AstraZeneca’s treatment for transthyretin amyloidosis (ATTR). Bernstein’s risk-adjusted revenue forecast for 2035 stands at $4.80 billion — representing a 170% premium over Bloomberg’s $1.80 billion consensus. AstraZeneca management has provided non-risk-adjusted peak sales guidance exceeding $5 billion.
Phase 3 CARDIO-TTransform trial results are anticipated during the latter half of 2026. Dr. Sharon Barr, who leads AstraZeneca’s non-oncology research and development, highlighted that U.S. diagnosis rates for ATTR cardiomyopathy currently hover around just 30% — signaling substantial unidentified patient populations.
Another promising candidate receiving analyst attention is AZD0780, an oral PCSK9 inhibitor targeting elevated cholesterol. Company guidance points to peak sales surpassing $5 billion; Bloomberg consensus projects $2.40 billion. Bernstein forecasts $3.10 billion by 2035.
Dr. Barr additionally noted that AZD0780 won’t require fasting protocols — potentially providing a competitive advantage versus Merck’s rival compound enlicitide decanoate.
COPD Treatment Strengthens Investment Thesis
Tozorakimab, AstraZeneca’s chronic obstructive pulmonary disease candidate, delivered positive phase 3 headline results on March 27, 2026. Company projections indicate peak sales ranging from $3 billion to $5 billion compared with Bloomberg’s $2 billion consensus.
Bernstein’s optimistic scenario envisions 179% upside to 2035 adjusted EBITA. The firm’s pessimistic case suggests 101% downside risk.
The currently approved product portfolio comprises 55% of the upside projection. Ultomiris leads this category, with Bernstein’s 2035 revenue estimate of $9.60 billion substantially exceeding consensus expectations of $6.50 billion.
Regarding valuation metrics, GuruFocus assigns AZN a GF Score of 83 out of 100. The current price-to-earnings ratio of 27.3x trades below the five-year median of 34.2x. GF Value calculation places fair value at $178.11 — marginally beneath the $181.80 trading price, indicating modest 2.1% overvaluation.
One consideration for investors: company insiders have sold $2.2 million in shares during the past three months, with zero buying transactions recorded.
Phase 3 CARDIO-TTransform data for Wainua represents the next significant catalyst, scheduled for release in the second half of 2026.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
